Bicycle Therapeutics Target Price. With 1 buy predictions and 1 sell predictions. Bicycle therapeutics company profile.
Its lead product candidate is bt1718 a bicycle toxin conjugate btc which is in phase i iia. Oppenheimer reissued a buy rating and set a 27 00 target price on shares of bicycle therapeutics in a research note on tuesday. With a target price of 18 00 there is a positive potential of 33 333 for bicycle therapeutics ltd.
There are currently 5 buy ratings for the.
The community is currently still undecided about bicycle therapeutics ltd. Its lead product candidate is bt1718 a bicycle toxin conjugate btc which is in phase i iia. Bicycle in collaboration with ddf is developing bicycles to modulate the activity of proteins implicated in the progression of dementia. A loss of 2 170 shows a downward development for bicycle therapeutics ltd.